The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10049 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinin resistance

NOT Open Access | Viability Screen of LOPAC1280 Reveals Tyrosine Kinase Inhibitor Tyrphostin A9 as a Novel Partner Drug for Artesunate Combinations To Target the Plasmodium falciparum Ring Stage

April 2, 2019 - 11:46 -- NOT Open Access
Author(s): 
Jie Xin Tong, Sarah E. L. Ang, Esther H. N. Tan and Kevin S. W. Tan
Reference: 
Antimicrob Agents Chemother 63:e02389-18

The emergence of artemisinin-resistant Plasmodium falciparum poses a major threat to current frontline artemisinin combination therapies.

How can interventions that target forest-goers be tailored to accelerate malaria elimination in the Greater Mekong Subregion? A systematic review of the qualitative literature

February 5, 2019 - 16:23 -- Open Access
Author(s): 
Stephanie D. Nofal, Thomas J. Peto, Bipin Adhikari, Rupam Tripura, James Callery, Thanh Mai Bui, Lorenz von Seidlein and Christopher Pell
Reference: 
Malaria Journal 2019 18:32, 1 February 2019

A more detailed characterization of forest activities is needed but research on this topic raises methodological challenges.

A single nucleotide polymorphism in the Plasmodium falciparum atg18 gene associates with artemisinin resistance and confers enhanced parasite survival under nutrient deprivation

October 30, 2018 - 15:46 -- Open Access
Author(s): 
Kimberly F. Breglio, Roberto Amato, Anna Katharina Simon, et al.
Reference: 
Malaria Journal 2018 17:391, 26 October 2018

These results suggest that the atg18 T38I polymorphism may provide additional resistance against artemisinin derivatives, but not partner drugs, even in the absence of kelch13 mutations, and may also be important in parasite survival during nutrient deprivation.

Effectiveness and safety of 3 and 5 day courses of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar

July 15, 2018 - 16:52 -- Open Access
Author(s): 
Kyaw Myo Tun, Atthanee Jeeyapant, Frank Smithuis, et al.
Reference: 
Malaria Journal 2018 17:258, 11 July 2018

Despite a high prevalence of k13 mutations, the current first-line treatment, AL, was still highly effective in this area of South-East Myanmar.

Medical Treatment: 

A novel field-based molecular assay to detect validated artemisinin-resistant k13 mutants

April 25, 2018 - 15:18 -- Open Access
Author(s): 
Laurence Vachot-Ganée, Nimol Khim, Didier Ménard, et al.
Reference: 
Malaria Journal 2018 17:175, 24 April 2018

The K13 ready-to-use bMx prototype assay, considered by the end-users as a user-friendly assay to perform (in shorter time than the K13 reference assay) and easy to interpret, was found to require less budget planning and had fewer logistical constraints.

NOT Open Access | Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance

March 20, 2018 - 14:32 -- NOT Open Access
Author(s): 
Souvik Bhattacharjee, Isabelle Coppens, Kasturi Haldar, et al.
Reference: 
Blood 2018 Volume: 131 Issue: 11 Pages: 1234-1247

Artemisinin resistance threatens worldwide malaria control and elimination.

Plasmodium falciparum Kelch 13 mutations and treatment response in patients in Hpa-Pun District, Northern Kayin State, Myanmar

November 29, 2017 - 15:31 -- Open Access
Author(s): 
Craig A. Bonnington, Aung Pyae Phyo, Elizabeth A. Ashley, Mallika Imwong, Kanlaya Sriprawat, Daniel M. Parker, Stephane Proux, Nicholas J. White and Francois Nosten
Reference: 
Malaria Journal 2017 16:480, 25 November 2017

This study provides evidence of artemisinin resistance in a remote part of eastern Myanmar.

Country: 

Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles

July 11, 2017 - 12:50 -- Open Access
Author(s): 
Kevin C. Kobylinski, Ratawan Ubalee, Jason H. Richardson, et al.
Reference: 
Malaria Journal 2017 16:280, 7 July 2017

Ivermectin is lethal to dominant GMS Anopheles malaria vectors and inhibits sporogony of P. vivax at safe human relevant concentrations.

NOT Open Access | Molecular Profile of Malaria Drug Resistance Markers of Plasmodium falciparum in Suriname

June 27, 2017 - 17:57 -- NOT Open Access
Author(s): 
Stella M. Chenet, Sheila Akinyi Okoth, Malti R. Adhin, et al.
Reference: 
Antimicrob. Agents Chemother. July 2017 vol. 61 no. 7 e02655-16

In Suriname, an artesunate monotherapy therapeutic efficacy trial was recently conducted to evaluate partial artemisinin resistance emerging in Plasmodium falciparum.

Pages

Subscribe to RSS - artemisinin resistance